Background: In humans, trophoblast invasion, vascular remodeling and placentation are critical to determine the fate of pregnancy. Since guinea-pigs (GP) and humans share common pregnancy features including extensive trophoblast invasion, transformation of the uterine spiral arteries and a haemomonochorial placenta, the GP animal model was deemed suitable to extend our knowledge on the spatio-temporal immunoreactive expression of the vasodilator arpeptide of the renin-angiotensin system, angiotensin-(1–7) [Ang-(1–7)] and its main generating enzyme, angiotensin converting enzyme 2 (ACE2).

Methods: Utero-placental units were collected in days 15, 20, 40 and 60 of a 64–67 day long pregnancy in 25 Pirbright GP. Ang-(1–7) and ACE2 expression in utero-placental units were evaluated by immunohistochemistry.

Results: Ang-(1–7) and ACE2 were detected in the endothelium and syncytiotrophoblast of the labyrinthine placenta, interlobium, subplacenta, giant cells, syncytial sprouts, syncytial streamers, and myometrium throughout pregnancy. In late pregnancy, perivascular or intramural trophoblasts in spiral and mesometrial arteries expressed both factors. Immunoreactive Ang-(1–7) and ACE2 were present in decidua and in the vascular smooth muscle of spiral, myometrial and mesometrial arteries, which also express kallikrein (Kal), the bradykinin receptor 2 (B2R), vascular endothelial growth factor (VEGF) and its type 2 receptor (KDR), but no endothelial nitric oxide synthase (eNOS). In addition, the signal of Ang-(1–7) and ACE2 was especially remarkable in giant cells, which also show Kal, B2R, eNOS, VEGF and KDR.

Conclusions: The spatio-temporal expression of Ang-(1–7) and ACE2 in GP, similar to that of humans, supports a relevant evolutionary conserved function of Ang-(1–7) and ACE2 in decidualization, trophoblast invasion, vascular remodeling and placentation flow regulation, as well as the validity of the GP model to understand the local adaptations of pregnancy. It also integrates Ang-(1–7) to the utero-placental vasodilatory network. However, its antiangiogenic effect may counterbalance the proangiogenic activity of some of the other vasodilator components.

Background
The outcome of pregnancy depends upon the success of placentation. In normal human pregnancy, extravillous trophoblasts (EVT) after anchoring in the uterine wall migrate through the decidualized stroma to invade the uterine spiral arteries. This last process destroys vascular smooth muscle and replaces the endothelium with EVT by the second trimester of pregnancy. This remodeling increases vessel diameter and creates a high flow, low resistance arteriolar system that meets the increased demands of the fetus across the barrier of the rich de novo vasculature of the placenta. The disturbance of this finely tuned orchestrated sequence causes important obstetric and neonatal complications that range from miscarriages due to failed attachment to the extensive invasion of placenta accreta. In the midst, a shallow invasion results in intrauterine growth retardation, or in a hypoperfused placenta which sheds to the maternal circulation microvillous particles and soluble factors that cause the clinical phase of preeclampsia. Among these factors, agonistic autoantibodies to angiotensin II receptor 1 (AT1-AA) participate in the physiopathology of preeclampsia, stressing the prominence of the renin-angiotensin system (RAS) in this condition [1,2].

* Correspondence: gvaldesst@gmail.com
1Centro de Investigaciones Médicas y Departamento de Nefrología, Escuela de Medicina, Pontificia Universidad Católica, Santiago, Chile
Full list of author information is available at the end of the article

© 2013 Valdés et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The RAS is a key regulator of systemic hemodynamics. In normal human pregnancy the vasoconstrictor peptide angiotensin II (Ang II) is elevated [3], but the counter-balancing vasodilator angiotensin-(1–7) [Ang-(1–7)] is increased in plasma and urine [4,5]. Angiotensin-converting enzyme 2 (ACE2), a pleiotropic monocarboxypeptidase [6], is the main Ang-(1–7) generating enzyme and influences the relative expression/functions of Ang II and Ang-(1–7). Ang-(1–7) most likely contributes to the reduction in the systemic vascular resistance and the maintenance of normal systemic blood pressure, as suggested by its defective response in preeclampsia [4] and by the increment of blood pressure in pregnant ACE2 knock-out mice [7]. Apart from vasoactive effects, Ang II stimulates proliferation and angiogenesis [8,9], while Ang-(1–7) is antiproliferative and antiangiogenic [10].

In human utero-placental tissues the traditional vasoconstrictor components of the RAS are ubiquitous [11–16]. As to vasodilator peptides and receptors of the RAS, Broughton-Pipkin and her group have recently shown higher early expression of the receptor of Ang IV in the sncytotrophoblast and extravillous trophoblast [12]; in addition, our laboratories have shown that Ang-(1–7) and ACE2 are expressed in multiple sites of the utero-placental interface [17,18].

Since vasodilators are key players in the hemodynamic local adaptations of pregnancy, we now aim at understanding the paracrine role of Ang-(1–7) and ACE2 in the utero-placental unit by evaluating the immunohistochemical expression of both factors in the guinea-pig. This caviomorph rodent shares with women: (a) a haemomochorial placenta; (b) similar progesterone levels and response to progesterone antagonists [19]; (c) an extensive trophoblast invasion and remodeling of the utero-placental arteries [20,21]; (d) the expression of paracrine factors implicated in vasodilation and trophoblast invasion, as matrix metalloproteases (MMPs), kallikrein (Kal), bradykinin 2 receptor (B2R), endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), VEGFR-2 (Flk-1/KDR) and VEGFR-1 (Flt-1) [22,23]; (e) pregnancy toxemia, observed in animals with spontaneous aortic stenosis below the renal arteries or with banded uterine arteries and transsected ovarian arteries [24,25]. Acquiring further information on the presence and localization of vasodilator components within the RAS in this species will help understand their participation in the local adaptations of human pregnancy.

Methods
Guinea-pigs (Pirbright white Cavia porcellus ~600 g) were housed under controlled humidity, temperature and light cycle conditions. Females were examined daily, and were caged with fertile males when perforation of the vaginal closure membrane occurred; the day a copulatory plug was observed was defined as day one of pregnancy. Twenty-five dams were sacrificed in early to term pregnancy, on days 15 (n = 4), 20 (n = 6), 40 (n = 7), and 60 (n = 8) of a 64–67 day pregnancy, after being anesthetized with an intraperitoneal injection of ketamine (100 mg/kg) and xylazine (4 mg/kg). The uterus was dissected and fetoplacental units (2–5 per dam) were removed; some were sagitally sliced and fixed in a single block, in others the placenta, endometrium, and mesometrium were separated. The animals were euthanized with an overdose of anesthesia. Tissues were fixed immediately with phosphate-buffered 4% formalin for 24 hours.

Ethical approval
The experiments were conducted according to the Guide for the Care and Use of Laboratory Animals (National Research Council, USA) and approved by the Ethics Committee of FONDECYT (Fondo Nacional de Desarrollo Científico y Tecnológico, Chile).

Immunohistochemistry
Fixed tissues were paraffin embedded, sectioned (5 μm), dehydrated in a graded series of ethanol and xylene and included in Paraplast-Plus® (Sigma, St. Louis, MO). Sections were deparaffinized in xylene and rehydrated in a graded alcohol series. Endogenous peroxidases were blocked with incubation in 10% H2O2 for 10 minutes. Sections were incubated in a humid chamber for 30 minutes with goat serum (Vector Laboratories, Burlingame, CA) as a protein block followed by incubation for 18 hours at 4°C with the primary antibodies. These antibodies were affinity-purified polyclonal rabbit anti-Ang-(1–7) (1:25) and anti-ACE2 (1:1000) produced by our group at Wake Forest School of Medicine [18,26]. Sections were immunostained using a biotin-streptavidin-peroxidase system (LSAB+, DakoCytomation, Carpinteria, CA). The specificity of the staining was determined by eliminating the primary antibody, incubating with non-specific immunoglobulin or by preadsorbing with the peptide to which the antibody was generated.

Cytotrophoblasts were identified by staining with an antipancytokeratin mouse monoclonal antibody (1:100, P2871, Sigma). Smooth muscle and endothelial cells were characterized with antibodies against α-smooth muscle actin (1A4, 1:1500) and von Willebrand factor (A0082, 1:400) respectively, both from DakoCytomation, Carpinteria, CA. The specificity of the staining was determined by eliminating the primary antibody, incubating with non-specific immunoglobulin or by preadsorbing with the peptide to which the antibody was generated.

Previous studies which were revised in the context of the present work [22,23] were performed with the following antibodies: rabbit polyclonal antiserum against purified rat urinary kallikrein (1:2000), mouse monoclonal anti-eNOS (1:50, BD Transduction Laboratories,
**Results**

In embryonic derived cells immunoreactivity for Ang-(1–7) (Figure 1A) and ACE2 (Figure 1B) was detected in the interlobium, endothelium and syncytiotrophoblast of the labyrinthine placenta, subplacenta, giant cells, syncytial sprouts, syncytial streamers and intravascular and intraluminal trophoblasts (Table 1).

In maternal tissues, decidua, vascular smooth muscle and endothelial cells of spiral and mesometrial arteries, as well as the myometrium, showed Ang-(1–7) and ACE2 (Figures 1 and 2, Table 1). The decidual expression of ACE2 was stronger in gestational days 15 and 20 as compared to day 40. In late gestation (day 60), the necrotic areas in the subplacenta, decidual cells, and streamers hindered the observation of the expression of Ang-(1–7) and ACE2 in these zones.

The signal for both Ang-(1–7) and ACE2 was especially remarkable in the markedly protrusive parietal giant cells that envelop the maternal blood sinuses with long cytoplasmic laminas (Figures 1 and 2).

Ang-(1–7) and ACE2 expression was coarsely granular in giant cells and vascular smooth muscle, finely granular in the labyrinth, interlobium and decidual cells, and diffuse with a peripheral reinforcement in syncytial streamers.

Temporal assessment showed that Ang-(1–7) and ACE2 were expressed throughout pregnancy in the giant cells, labyrinth and myometrial arteries. As early as day 15 of gestation, invasive trophoblasts coalesced into syncytial streamers and migrated into the endometrium; their immunoreactive expression of Ang-(1–7) and ACE2 was more intense in early and mid pregnancy as compared to late pregnancy, when streamers were diminished. In the myometrium, spiral arteries were surrounded by Ang-(1–7) and ACE2 positive trophoblasts. In days 40 and 60 of late gestation, uterine and mesometrial arteries were multilayered, and displayed Ang-(1–7) and ACE2 in vascular smooth muscle and invading trophoblasts.

Control sections incubated with non-specific immunoglobulin or in the absence of the first antibody yielded no staining in different structures and stages of pregnancy (not shown). Sections preincubated with an excess of peptide that corresponds to the epitope recognized by the antibody showed no immunoreactive signal for Ang-(1–7), while for ACE2 some background staining persisted (Figure 2).
Table 1 Distribution of Angiotensin-(1–7) and ACE2 in the guinea-pig utero-placental unit in early (day 15), mid (days 20 and 40) and late (day 60) gestation

| Day of Gestation | Giant cells | Interlobium | Labyrinth | Subplacenta | Decidual cells | Streamers | Spiral arteries | SM spiral arteries | Myometrium | Mesometrium |
|------------------|-------------|-------------|-----------|-------------|----------------|-----------|-----------------|-------------------|-------------|-------------|
| Ang-(1–7)        |             |             |           |             |                |           |                 |                   |             |             |
| Day 15           | +           | +           | Not recognizable | ±           | +              | +         | VSM             | +                 | +           | VSM         |
| Day 20           | +           | +           | +         | +           | VSM           | +         | +               | VSM               |             |             |
| Day 40           | +           | SCT, endothelium | SCT, endothelium | +         | +              | VSM       | +               | VSM               | +           |             |
| Day 60           | +           | +           | +         | Necrotic     | Necrotic       | Necrotic  | VSM, IVTB        | +                 | +           | VSM, endothelium |

ACE2

| Day of Gestation | Giant cells | Interlobium | Labyrinth | Subplacenta | Decidual cells | Streamers | Spiral arteries | SM spiral arteries | Myometrium | Mesometrium |
|------------------|-------------|-------------|-----------|-------------|----------------|-----------|-----------------|-------------------|-------------|-------------|
| Day 15           | +           | +           | Not recognizable | ±           | +              | +         | VSM             | +                 | +           | VSM         |
| Day 20           | +           | +           | +         | +           | +              | VSM       | +               | VSM               | +           |             |
| Day 40           | +           | SCT, endothelium | SCT, endothelium | +         | ±              | ±         | VSM             | +                 | +           | VSM         |
| Day 60           | +           | SCT, endothelium | SCT, endothelium | Necrotic     | Necrotic       | Necrotic  | VSM, IVTB        | VSM, IVTB         | +           | VSM, endothelium |

SCT = syncytiotrophoblast; IVTB = intravascular trophoblast; VSM = smooth muscle. Necrotic areas in late gestation in the central portion of the utero-placental unit were identified by the disruption of the tissues. Negative and positive sections observed in different animals, or faint signal (±); positive signal in all animals (+).
Discussion

The spatio-temporal expression of Ang-(1–7) and ACE2 in sites related to decidualization, trophoblast invasion, vascular remodeling, placental flow regulation and platelet antiaggregation supports a relevant role of these peptides/proteins in the gestation of the guinea-pig.

The coincident location of Ang-(1–7) and ACE2 in the guinea-pig and in equivalent human structures as reported by Pringle et al. [11] and by us [18] endorses an evolutionary conserved role, and provides further confirmation of the validity of the guinea-pig model to understand human pregnancy. The shift of the predominance of Ang II in the uterine fundus to Ang-(1–7) in the placental bed [18] and the increased expression of Ang-(1–7) and ACE2 mRNA in early pregnancy as compared to normal term pregnancy [17] are indicative of an early vasodilatory effect on the maternal vasculature.

Rats, as guinea-pigs, express Ang-(1–7) and ACE2 staining in the labyrinthine placenta [26]. The marked decrement of placental and uterine Ang-(1–7) concentrations in the reduced uterine perfusion pressure rat model of hypertensive pregnancy [26] supports a role of this vasodilator in normotensive pregnancy.

The localization of Ang-(1–7) in the same cell types that express other vasodilator factors in this species (Kal, the B2R, eNOS, VEGF and KDR) [22,23] highlights the importance and complexity of the utero-placental vasodilator network [27]. As in women, Ang-(1–7) and ACE2 in the guinea pig are additionally expressed in decidual cells. The vascular smooth muscle of myometrial and mesometrial

Figure 2 Immunoreactive expression of Ang-(1–7) and ACE2 in giant cells (GC) and labyrinth (LAB), from a gestational day 60 pregnant guinea-pig. Sections were preincubated with and without the immunizing peptide. (x400).

Figure 3 Sequential sections of the myometrial artery in gestational day 40, which in Figure 1A and B displays immunoreactivity for Ang-(1–7) and ACE2. These show a moderate signal for kallikrein (Kal), a faint and scanty one for bradykinin R2 (B2R), vascular endothelial growth factor (VEGF) and its type 2 receptor (KDR), and no endothelial nitric oxide synthase (eNOS), in vascular smooth muscle (VSM) characterized by α-smooth muscle actin. These vasodilators are present in endothelial cells characterized by von Willebrand factor (vWF). Absence of cytokeratin (CK) positive cells demonstrates no intraarterial extravillous trophoblasts. (x200).
arteries display intense immunoreactivity for Ang-(1–7) and ACE2, a moderate signal for kallikrein, a faint signal in scant cells for B2R, VEGF and KDR and absence of eNOS (Figure 3). This localization of the paracrine/autocrine vasodilator components of the RAS in both maternal and fetal components of the utero-placental unit, suggests their instrumental participation in trophoblast invasion and spiral artery remodeling. The preparation of arteries for trophoblast invasion has been mainly attributed to the nearby trophoblasts, uterine natural killer cells and macrophages. In this case, it is feasible that Ang-(1–7) generated by the vascular smooth muscle interacts with NO liberated by its "pacemaker", the approaching trophoblast [28]. The relevance of uterine artery vasodilatation in pregnancy has been underscored in the ewe, by the demonstration that even vasoconstrictor Ang II induces in them PGI2 and NO endothelial production [29].

The intense expression of Ang-(1–7) and ACE2 in giant cells observed in this study made us re-assess in them our previous analysis on the immunoreactive expression of the vasodilator panel in the guinea pig [22,23]. In sequential sections we found a strong immunoreactive signal for VEGF and a moderate signal for kallikrein, the B2R, eNOS, and KDR (Figure 4). In future studies the prominence of Ang-(1–7) and ACE in parietal giant cells needs to be examined in regard to their functional importance in decidualization, trophoblast invasion, synthesis of a wide range of hormones, angiogenic and vasodilatory factors (VEGF, NO) and glycogen and glycoproteins storage [28,30]. If their hormonal production is disturbed, vascularization of the decidua is compromised, and embryos present lethal defects. In mice, inhibition or overabundance of giant cells are equally detrimental.

In contrast to VEGF, NO, bradykinin and Ang II, pleiotropic Ang-(1–7) is a potent antiangiogenic factor, which impairs tube formation by human umbilical cells [31], growth of tumors and tumoral cells and vascularization of sponge implants [32-34]. The importance of ACE2 in mediating the Ang II-Ang-(1–7) balance is supported by growth of pancreatic cancer cells when its mRNA is silenced and by inhibition of tumor expansion when the enzyme is overexpressed [35].

The localization of Ang-(1–7) and ACE2 in different structures of the guinea-pig utero-placental unit tallies with a role of these factors in the regulation of trophoblast invasion, angiogenesis and blood flow. The findings described herein show that the guinea-pig represents an attractive model to manipulate the opposing arms of the RAS in order to understand the functionality of the system in the systemic and local adaptations of pregnancy. Adding a new species to the mice and rat models now in use will especially contribute to the study of the placental bed along pregnancy, since this crucial territory is out-of-bounds for research in ongoing human pregnancies.

Conclusions
The spatio-temporal expression of Ang-(1–7) and ACE2 in GP, similar to that of humans, supports a relevant evolutionary conserved function of Ang-(1–7) and ACE2 in decidualization, trophoblast invasion, vascular remodeling and placental flow regulation, as well as the validity of the GP model to understand the local adaptations of pregnancy. It also integrates Ang-(1–7) to the utero-placental vasodilatory network. However, its antiangiogenic effect may counterbalance the proangiogenic activity of some of the other vasodilatory components.

Figure 4 Giant cell (GC) expression of vasodilator factors. The signal is intense for vascular endothelial growth factor (VEGF), moderate for its type 2 receptor (KDR), kallikrein (Kall), the bradykinin B2 receptor (B2R) and endothelial nitric oxide synthase (eNOS) in two different sets of sequential sections (upper and lower panels). Asterisks indicate the same cell in each panel. Visceral yolk sac=VYS, interlobium=IL. (x400).
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
The study was conceived by GV and KBB; the design, the histological analysis, the interpretation of the data and the drafting of the manuscript were done by GV and JC; JC sacrificed the animals and prepared the tissue sections; she and DS performed the immunohistochemistry of non-RAS factors; MSB and JJ performed the immunohistochemistry for Ang-(1–7) and ACE2; KBB participated in the analysis of the data and in the different versions of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by FONDECYT grants (1080228 and 1121161) and POI-NHLBI-51952. The authors gratefully acknowledge support in part by Uniril, Greensboro, NC, Farley-Hudson Foundation, Jacksonville, NC, and by two Chilean private donations.

Author details
1Centro de Investigaciones Médicas y Departamento de Nefrología, Escuela de Medicina, Pontificia Universidad Católica, Santiago, Chile. 2Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Received: 7 September 2012 Accepted: 14 January 2013

References
1. Wallukat G, Hornuth V, Fischer T, Lindschau C, Horstkamp B, Junper A, Baur E, Nissen E, Vetter K, Niechel D, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999, 103:945–952.
2. Xia Y, Ramin SM, Kelkens RE: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007, 50:269–275.
3. Wilson M, Morganti AA, Zervoudakis I, Lechter RL, Romney BM, Von Oeyn P, Papeira S, Sealey JE, Laragh JH: Blood pressure, the renin-aldosterone system and sex steroids throughout normal pregnancy. Am J Med 1980, 68:97–104.
4. Merrill DC KM, Chen K, Ferrario CM, Brosnihan KB: Angiotensin-(1–7) in normal and preeclamptic pregnancy. Endocrine 2002, 18:239–245.
5. Valdés G, Germain AM, Corthorn J, Benito C, Foradori AC, Ferrario CM, Brosnihan KB: Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 2001, 16:117–122.
6. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-Dos Santos AI, da Costa J, Zhang L, Pei Y, et al: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822–828.
7. Bharadwaj MS, Strawn WB, Groban L, Yamaleyeva YM, Chappell MC, Horta C, Atkins K, Firmyes L, Gurley SB, Brosnihan KB: Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 2011, 58:852–858.
8. Touyz RM, Deng LY, He G, Wu XM, Schiffrin EL: Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertension 1999, 17:907–916.
9. Zhang F, Hu Y, Xu Q, Ye S: Different effects of angiotensin II and angiotensin-(1–7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010, 5:e12323.
10. Tallant EA, Dui DL, Ferrario CM: State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1–7) in vascular smooth muscle. Hypertension 1999, 34:950–957.
11. Pringle KG, Tadros MA, Callister RJ, Lumbergs ER: The expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis? Placenta 2011, 32:956–962.
12. Williams PJ, Mistry HD, Innes BA, Bulmer JN, Broughton Pipkin F: Expression of AT1R, AT2R and AT4R and their roles in extravillous trophoblast invasion in the human. Placenta 2012, 31:448–455.
13. Acker GM, Galen FX, Devaux C, Foote S, Papernik E, Pesty A, Menard J, Contol P: Human choriocarcinoma cells in primary culture: a model for renin biosynthesis. J Clin Endocrinol Metab 1982, 55:902–909.
14. Hodari AA, Smeyb R, Bumpus FM: A renin-like substance in the human placenta. Obstet Gynecol 1967, 29:313–317.
15. Symonds EM, Stanley MA, Skinner SL: Production of renin by in vitro cultures of human chorion and uterine muscle. Nature 1968, 217:1152–1153.
16. Shaw KJ, Do YS, Kjos S, Anderson PW, Shinagawa T, Dubeau L, Hsueh WA: Human decidua is a major source of renin. J Clin Invest 1989, 83:2085–2092.
17. Valdés G, Neves LA, Anton L, Corthorn J, Chacon C, Germain AM, Merrill DC, Ferrario CM, Sarao R, Penninger J, Brosnihan KB: Distribution of angiotensin-(1–7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006, 27:200–207.
18. Antón L, Merrill DC, Neves LA, Diz DI, Corthorn J, Valdés G, Stovall K, Gallagher PE, Moorefield C, Grüber C, Brosnihan KB: The uterine placental bed renin-angiotensin system in normal and preeclamptic pregnancy. Endocrinology 2009, 150:4316–4325.
19. Elder W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000, 65:713–723.
20. Nanaev A, Chwalisz K, Frank HG, Kohen G, Hegele-Hartung C, Kaufmann P: Physiological dilation of uteroplacental arteries in the guinea pig depends on nitric oxide synthase activity of extravillous trophoblast. Cell Tissue Res 1995, 282:407–421.
21. Mess A, Zaki N, Kodroy M, Kor H, Kaufmann P: Caviomorph placentation as a model for trophoblast invasion. Placenta 2007, 28:1234–1238.
22. Valdes G, Erices R, Chacon C, Corthorn J: Angiogenic, hyperpermeability and vasodilator network in utero-placental units along pregnancy in the guinea-pig (Cavia porcellus). Reprod Biol Endocrinol 2008, 6:13.
23. Corthorn J, Rey S, Chacon C, Valdes G: Spatio-temporal expression of MMP-2, MMP-9 and tissue kallikrein in uteroplacental units of the pregnant guinea-pig (Cavia porcellus). Reprod Biol Endocrinol 2007, 5:27.
24. Seid DC, Hughes HC, Bertollet R, Lang CM: True pregnancy toxemia (preeclampsia) in the guinea pig (Cavia porcellus). Lab Anim Sci 1979, 29:472–478.
25. Golden JS, Hughes HC, Lang CM: Experimental toxemia in the pregnant guinea pig (Cavia porcellus). Lab Anim Sci 1980, 30:174–179.
26. Neves LA, Stovall K, Joyner J, Valdés G, Gallagher PE, Ferrario CM, Merrill DC, Brosnihan KB: ACE2 and ANG-(1–7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol 2008, 294:R151–R161.
27. Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Granthings J: Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol 2009, 7:79.
28. Kaufman P, Black S, Huppertz B: Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod 2003, 69:1–7.
29. Magnes RR, Rosenfeld CR, Hassan A, Shaul PW: Endothelial vasodilator production by uterine and systemic arteries. E Effects of ANG II on PGII and NO in pregnancy. Am J Physiol 1996, 270:R1914–1923.
30. Hemmerber M: IFPA award in placentology lecture - characteristics and significance of trophoblast giant cells. Placenta 2008, 29(Suppl A):4–9.
31. Antón L, Merrill DC, Neves LA, Brosnihan KB: Angiotensin-(1–7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT1(–7) receptor. Endocrine 2007, 27:12–218.
32. Gallagher PE, Tallant EA: Inhibition of human lung cancer cell growth by angiotensin-(1–7). Cancerogenesis 2004, 25:2045–2052.
33. Soto-Pantoja DR, Menon J, Gallagher PE, Tallant EA: Angiotensin-(1–7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009, 8:1676–1683.
34. Machado RD, Santos RA, Andrade SP: Mechanisms of angiotensin-(1–7)-induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol 2001, 280:R994–R1000.

35. Zhou L, Zhang R, Zhang L, Yao W, Li J, Yuan Y: Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy. Cancer Lett 2011, 307:18–25.

doi:10.1186/1477-7827-11-5

Cite this article as: Valdés et al.: Utero-placental expression of angiotensin-(1–7) and ACE2 in the pregnant guinea-pig. Reproductive Biology and Endocrinology 2013 11:5.